Literature DB >> 20541829

Modeling the glucose regulatory system in extreme preterm infants.

Aaron Le Compte1, J Geoffrey Chase, Glynn Russell, Adrienne Lynn, Chris Hann, Geoffrey Shaw, Xing-Wei Wong, Amy Blakemore, Jessica Lin.   

Abstract

BACKGROUND: Premature infants represent a significant proportion of the neonatal intensive care population. Blood glucose homeostasis in this group is often disturbed by immaturity of endogenous regulatory systems and the stress of their condition. Hypo- and hyperglycemia are frequently reported in very low birth weight infants, and more mature infants often experience low levels of glycemia. A model capturing the unique fundamental dynamics of the neonatal glucose regulatory system could be used to develop better blood glucose control methods.
METHODS: A metabolic system model is adapted from adult critical care to the unique physiological case of the neonate. Integral-based fitting methods were used to identify time-varying insulin sensitivity and non-insulin mediated glucose uptake profiles. The clinically important predictive ability of the model was assessed by assuming insulin sensitivity was constant over prediction intervals of 1, 2 and 4h forward and comparing model-simulated versus actual clinical glucose values for all recorded interventions. The clinical data included 1091 glucose measurements over 3567 total patient hours, along with all associated insulin and nutritional infusion data, for N=25 total cases. Ethics approval was obtained from the Upper South A Regional Ethics Committee for this study.
RESULTS: The identified model had a median absolute percentage error of 2.4% [IQR: 0.9-4.8%] between model-fitted and clinical glucose values. Median absolute prediction errors at 1-, 2- and 4-h intervals were 5.2% [IQR: 2.5-10.3%], 9.4% [IQR: 4.5-18.4%] and 13.6% [IQR: 6.3-27.6%] respectively.
CONCLUSIONS: The model accurately captures and predicts the fundamental dynamic behaviors of the neonatal metabolism well enough for effective clinical decision support in glycemic control. The adaptation from adult to a neonatal case is based on the data from the literature. Low prediction errors and very low fitting errors indicate that the fundamental dynamics of glucose metabolism in both premature neonates and critical care adults can be described by similar mathematical models.
Copyright © 2010. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541829     DOI: 10.1016/j.cmpb.2010.05.006

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  5 in total

1.  Characterisation of the iterative integral parameter identification method.

Authors:  Paul D Docherty; J Geoffrey Chase; Timothy David
Journal:  Med Biol Eng Comput       Date:  2011-12-29       Impact factor: 2.602

2.  A C-Peptide-Based Model of Pancreatic Insulin Secretion in Extremely Preterm Neonates in Intensive Care.

Authors:  Jennifer L Dickson; Jane Alsweiler; Cameron A Gunn; Christopher G Pretty; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2015-08-07

3.  Nasogastric aspiration as an indicator for feed absorption in model-based glycemic control in neonatal intensive care.

Authors:  Cameron A Gunn; Jennifer L Dickson; James N Hewett; Adrienne Lynn; Hamish J Rose; Sooji H Clarkson; Geoffrey M Shaw; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2013-05-01

4.  Pilot study of a model-based approach to blood glucose control in very-low-birthweight neonates.

Authors:  Aaron J Le Compte; Adrienne M Lynn; Jessica Lin; Christopher G Pretty; Geoffrey M Shaw; J Geoffrey Chase
Journal:  BMC Pediatr       Date:  2012-08-07       Impact factor: 2.125

5.  Physiological modeling, tight glycemic control, and the ICU clinician: what are models and how can they affect practice?

Authors:  J Geoffrey Chase; Aaron J Le Compte; J-C Preiser; Geoffrey M Shaw; Sophie Penning; Thomas Desaive
Journal:  Ann Intensive Care       Date:  2011-05-05       Impact factor: 6.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.